Skip to content

King Pharmaceuticals KG European Hospital Liability — Year 4

Other product segments

Commercial Auto Liability
18.2%
General Liability
15.9%
All other lines
4.7%
International
-0.3%

Similar metrics at other companies

American International Group logo
AIGUK/Europe Casualty and Financial lines — Year 4 (as a percent)
10.3%-0.5pp
Greenlight Capital RE, Ltd. logo
GLREFinancial — Year 4
36%+7.2pp
Axis Capital Holders logo
AXSInsurance — Year 4
14.8%
Greenlight Capital RE, Ltd. logo
GLREHealth — Year 4
0%
American International Group logo
AIGUK/Europe and Japan Personal Insurance — Year 4 (as a percent)
3.3%-0.2pp
CNA Financial logo
CNAMedical Professional Liability — Year 4
16.7%+0.1pp

Other financials

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M
Total equity$121.4M+2,773%
Total assets$964.2M

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation

See full
Market cap$70.42M-67.6%
Enterprise value$184.93M-50.0%
P/E1.2×
P/S1.6×-24.3×

Profitability

See full
Net margin131.5%

Returns & leverage

See full
Return on equity90.8%
Debt / equity1.5×

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearFour.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's european hospital liability — year 4.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is King Pharmaceuticals's european hospital liability — year 4?
King Pharmaceuticals (KG) reported european hospital liability — year 4 of 13.7% in Q4 2025.
What does european hospital liability — year 4 mean?
This metric captures the financial performance or claim development for the fourth year of the underwriting cycle within the European Hospital Liability segment. It is essential for evaluating the long-term accuracy of reserve estimations and the ultimate settlement costs for mature claims in this segment.